ТЕРАПИЯ АНТИМАЛЯРИЙНЫМИ (АМИНОХИНОЛИНОВЫМИ) ПРЕПАРАТАМИ И БЕЗОПАСНОСТЬ ОРГАНА ЗРЕНИЯ

1. <div><p>НасоновЕ.Л. Антималяриииые (амииохниолииовые) препараты: новые фармакологические свойства и перспективы клинического применения. Клииич фармакол. и тер., 1998, 3, 65-68.</p><p>Arden G.B. Kolb Н, Antimalarial therapy and early retinal changes ill patients with rheumatoid arthritis. Br. Med. J., 1966. I. 270-273.</p><p>Aylward J.M, Hydroxychloroquine and chloroquine: assessing the risk of the toxi-city. J. Am. Ophtlalmol, Assoc., 1993, 64, 787-797.</p><p>Bartholomew L.E., DufT I.F.Amopyroquine (Propoquin) in rheumatoid arthritis. Arthr. Rheum., 1963, 6, 356-3634.</p><p>Berliner R.W., Earle D., Taggcrt J. et al. Studies on the chemotherapy of human malarias. VI The physiological deposition, antimalarial activity and toxicity of several derivatives of 4-aminoquinolines. J. Clin. Invest., 1948, 27 (suppl.), 60.</p><p>BernstcinH.N., Ginsberg.[.The pathology of chloroquine retinopathy. Arch. Ophtalmol., 1964, 71, 238.</p><p>Bienfang D., Coblyn J.S., Liang M.H., Corzillius M. Hydroxychloroquine retinopathy despite regular ophthalmologic evaluation - a consecutive series. J.Rheumatol., 2000, 27, 2703-2706.</p><p>Blyth C. Lane C, Hydroxychloroquine retinopathy; is screening necessary? Br Med.J., 1998, 916, 710-727.</p><p>Burns R, Delayed oncet of chloroquine retinopathy, N. Engl. J. Med,, 1966, 275, 693-696. 10. Butler I.Retinopathy following the use of chloroquin and allied substanecs. Ophtalmol., 1965, 149, 204-206. 11. Cambioggi A.Unusual ocular lesions in a case lupus erithematosis. Arch. Ophthalmol., 1957, 57, 551-453. 12. Carr R.E., Gouras P., Gunkel O.D. Chloroquine retinopathy. Arch. Ophtalmol., 1966, 75, 171-178. 13. Carr R.E.. Henkind P., Rothfield N., Siegel I.M. Ocular toxicity of anlimalarial drugs: long-term follow-up Am.J. Ophthalmol., 1968, 66, 738-744. 14. Crews S.J. Chloroquine retinopathy with recover)' in early stages. Lancet, 1964, 2. 436-438. 15. Easterbrook M. Detection and prevention of maculopathy associated with anlimalarial agents. Int. Ophtalmol. Clin., 1999, 39, 49-57</p><p>Easterbrook M.En Ophtalmological view on the efficacy and safety of chloroquine versus hydrochloroquine. J.Rheumatol., 1999^ 26. 1866-1867.</p><p>Easterbrook M.Is corneal deposition of anlimalarial any indication of retinal toxilicy? Can. J, Ophthalmol., 1990, 25, 249-251.</p><p>Elkington J.R., Hulh EJ.Letters and comments: chloroquine in rheumatoid arthritis. Ann.Intern.Med., 1965, 62, 1066-1067.</p><p>Falcone М., Paolini L., Lou L. Hydroxychloroquine toxicity despite normal dose therapy. Ann.Ophlhalmol., 1993, 25. 385388.</p><p>Freedman A., Steinberg L.Chloroquine in rheumatoid arthritis: A double-blind folfd trial of treatment for one year. Ann.Rheum.Dis., 1960, 19, 243-250.</p><p>Gruess A.F., Schachet A., Nicholl J.et al. Chloroquine retinopathy: is fluorescein angiography necessary1? Ophthalmol., 1985, 92, 1127-1129.</p><p>Hobbs H.E., Sorsby Д., Freedman A. Reinopathy following chloroquine therapy. Lancet, 1959, 2, 478-480.</p><p>Hollander J.L. The calculated risk of arthritis treatment. Ann. Intern. Med., 1965, 62. 1062-1064.</p><p>Levy G.D. Munz S.J., Paschal J.et al. Incidence of hydroxychloroquine retinopathy in 1207 patients in a large multicenier outpatient practice. Arthr. Rheum., 1997, 40, 14821486.</p><p>Mackenzie A.H. Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials. Am. J.Med,, 1983, 75, 40-45.</p><p>Mavrikukis М., Papazoglon S„ Saikiakis H. el al. Retinal toxicity in long term hydroxychloroquine treatment. Ann.Rheum.Dis., 1996, 55, 187-i89. '</p><p>Morand E.F., McCloud I., Littejohn G.O. Continuation of long term treatment with hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis. Ann. Rheum.Dis, 1992, 51, 1318-1321.</p><p>Morsman C.D.G., Liversey S.J., Richards I.M. el al.Screening for hydroxychloroquine retinal toxicily: is it necessary? Eye, 1990, 4, 572-576.</p><p>Nylander U.Ocular damage in chloroquine therapy. Acta Ophtalmol., 1966, 44, 335-348.</p><p>Okun G., Gouras , Bernstein H., Von Sallman L. Chloroquine retinopathy. Arch. Ophttalmol., 1963, 69, 59-71. Ophtalmol., 1964, 71, 157-165.</p><p>Percival S. B., Berhman J. Ophlhalmological safety of chloroquine. Br.J.Ophttalmol. 1969. 53, 101-109.</p><p>Percival S. В., Meanock I. Chloroquine: ophlhalmological safety, and clinical assessmenl in rheumatoid arthritis. Br.Med.J., 1968, 3, 579-584.</p><p>Popert A.J. Meyers K.A.E., Sharp J. Chloroquine diphosphate in rheumatoid arthritis, a controlled trial. Ann. Rheum. Dfis., 1961, 20, 18-35.</p><p>Puavilai S. Kunavisarut S., Vatanasuk M. el al.Ocular loxicily of chloroquin among Thai palients. Inl.J.Dermatol., 1999, 38, 934-937.</p><p>Raines M.F., Bhargava S.K., Rosea G.S. The blood-retinnal barrier in chloroquine retinopalhy. Invest. Ophttalmol., Vis.Sci^ 1998, 30, 1726-1731.</p><p>Reynes R.I., Kronel G. Falbo A. et al. Ophtlalmologic safely of long-term hydroxychloroquine treatment. Arthritis Rheum , 1979. 22, 832-836.</p><p>Reynes R.l. Ophtalmologic considerations in using antimalarials in the Uniled States. Lupus, 1996, 5, suppl 1, 73-74. 3S. Rynes R.Antimalarial drugs. In: Textbook of rheumatology, ed. W.Kelley, E.Harris, S.Ruddy, C.Sledge, W.B.Saunders. 1993. 731-742.</p><p>Royal College of OpIUtalmologists. Ocular toxicily and hydroxychloroquine. Guidelines for screening. 1998.</p><p>Rubin M.L., Thomas W.C. Diplopia and loss of accommodation due to chloroquine. Arthr. Rheum., 1970, 13, 75.</p><p>Ruiz R.S., Saatei O.A. Chloroquine and hydroxychloroquine relinopalhy: how to follow affected patients. Ann. Ophthalmol., 1991, 23, 290-291.</p><p>Sachs D.D., Hoban M.J. Engleinan E. Chorioretinopathy induced by chronic administration of chloroquine phosphate. Arthritis Rheum., 1962, 5, 318-319.</p><p>Sassman F.W., Cassidy J.T., Alpern М., Maaseidvaag Electroretinography in patients with connective tissue diseases treated with hydroxychloroquine. Am. J. Ophtalmol., 1970, 71, 515-523.</p><p>Scherbel A.L., Mackenzie A.H., Nousek J.E., Aidjian M.Ocular lesions in rheumatoid arthritis and related disorders wilh particular reference to retinopalhy: a study of 741 patients treated with and without chloroquine drugs. N. Engl. J. Med. 1965, 273, 360-366.</p><p>Shipley M„ Silman A.Should patients on hydroxychloroquine have their eyes examined regularly? Bril. J.Rheumatol., 1997, 36, 514-515.</p><p>Tobin D.R., Krohel G.B., Reynes R.I.: Hydroxychloroquine. A seven-year experience. Arch. Ophtalmol., 1982, 100, 478.</p><p>Voipio H.Incidence of chloroquine relinopalhy. Acta Ophthalmol., 1966, 44, 349-354.</p><p>Vu B.L., Easterbrook М., Hovis J.K. Detection of color vision defects in chloroquine retinopalhy. Ophtalmol., 1999, 106, 17991803.</p><p>Wallace D.J.Antimalarial therapies. In: Wallace D.J., Hahn B. H., eds. Dubois'Lupus Erythematosus, 4th edn. Philadelphia: Lea&amp;Febiger, 1993, 563-573.</p><p>Weise E.E., Yarronzzi L.A. Ring maculopathies mimicking chloroquine retinopalhy. Am.J.Ophlalmol., 1974, 78, 204-210.</p><p>Young , Rardin Т., Lankford B. et al. The apparent elimination of chloroquine retinopathy. Arthr. Rheum., 1974, 15, 464.</p></div><br />